Amicus Therapeutics, Inc.
http://www.amicusrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amicus Therapeutics, Inc.
Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark
The company hopes to score a nod from the US FDA based on a secondary endpoint that won approval for Sanofi’s Lumizyme.
Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Gene Therapies Dominate New Crop Of EU PRIME Recipients
Among the six new investigational products to make it onto the European Medicines Agency’s priority medicines scheme, five were gene therapies.
Sanofi Files New Pompe Hope Avalglucosidase Alfa In EU
The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Callidus Biopharma
- Celenex
- MiaMed, Inc.
- Scioderm, Inc.